<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03134586</url>
  </required_header>
  <id_info>
    <org_study_id>ANDI 1</org_study_id>
    <nct_id>NCT03134586</nct_id>
  </id_info>
  <brief_title>Advanced Non-Invasive Diagnostics in Inflammatory Bowel Disease</brief_title>
  <acronym>ANDI</acronym>
  <official_title>A Comparative Study of the Diagnostic Validity of Ultrasound, Magnetic Resonance Imaging and Capsule Endoscopy of Both the Small and Large Intestine in Suspected Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sydvestjysk Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sygehus Lillebaelt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sydvestjysk Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Non-invasive endoscopic procedures (pillcam
      colon capsule endoscopy, PCCE) and non-ionizing radiological modalities (MR
      enterocolonography, MREC and ultrasound, US) - offer a sufficiently high diagnostic validity
      in patients with suspected CD compared to the traditional invasive approach using
      ileocolonoscopy with biopsies as first line diagnostic modality
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, blinded, multicenter study of the diagnostic validity, inter-observer
      agreement, image quality and subjective experience of discomfort with PCCE, MREC and US in
      patients with suspected CD. Ileocolonoscopy serves as the diagnostic gold standard. Patients
      are recruited from 3 centers in the Region of Southern Denmark managing adult patients with
      inflammatory bowel diseases. Each patient goes through a standardized work-up including
      medical history, physical examination, C-reactive protein, fecal calprotectin,
      ileocolonoscopy, PCCE, MREC and US. All examinations are reviewed and described in a
      standardized fashion. The radiologists and physicians describing PCCE, MREC, and US are
      blinded to the findings at ileocolonoscopy and the other imaging modalities.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and specificity of PCCE, MREC and US for the diagnosis of CD</measure>
    <time_frame>36 months</time_frame>
    <description>Sensitivity and specificity of PCCE, MREC and US for the diagnosis of CD located in the terminal ileum and colon (per patient &amp; per segment). Ileocolonoscopy serves as gold standard</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of disease severity</measure>
    <time_frame>36 months</time_frame>
    <description>Correlation of disease severity assessed with PCCE, MREC, US and ileocolonoscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inter-observer agreement</measure>
    <time_frame>36 months</time_frame>
    <description>Inter-observer agreement with PCCE, MREC, US and ileocolonoscopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic yield of proximal CD</measure>
    <time_frame>36 months</time_frame>
    <description>Diagnostic yield of PCCE, MREC and US for CD located proximal to the terminal ileum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients reported experience</measure>
    <time_frame>36 months</time_frame>
    <description>Patients' subjective experience of discomfort during PCCE, MREC, US and ileocolonoscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interobserver PCCE</measure>
    <time_frame>36 months</time_frame>
    <description>Sensitivity and specificity of PCCE with different reading protocols</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Utility of diffusion weighed magnetic resonance imaging (dw-MREC) and US Doppler flow</measure>
    <time_frame>36 months</time_frame>
    <description>Utility of diffusion weighed magnetic resonance imaging (dw-MREC) and US Doppler flow (Limberg score): Sensitivity, specificity and correlation with endoscopic disease activity</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Crohn Disease</condition>
  <arm_group>
    <arm_group_label>trial participant</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All participants undergoes the same diagnostic imaging</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diagnostic imaging</intervention_name>
    <arm_group_label>trial participant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        General criterion

        All of the following:

          -  Clinical suspicion of CD

          -  Age &gt; 15 years

          -  Negative serologic markers for celiac disease, negative stool culture (or polymerase
             chain reaction) for pathogenic bacteria and a negative microscopy for intestinal
             parasites

          -  Fecal calprotectin &gt; 50 mg/kg

          -  Signed informed consent

        Clinical criterion Diarrhea and/or abdominal pain for more than 1 month (or repeated
        episodes of diarrhea and/or abdominal pain) associated with one or more of the following
        findings: (1) C-reactive protein (CRP) &gt;5 mg/L, (2) thrombocytosis (&gt; 400 x 109/L), anemia
        (hemoglobin &lt; 7.0 mmol/L for women and &lt; 8.0 mmol /L for men or a decrease &gt; 0.5 mmol/L
        compared to the usual level), (3) prolonged fever (&gt; 37.5 C for more than 2 weeks), (5)
        weight loss (≥ 3 kg or ≥ 5% compared to the normal body weight), (6) perianal
        abscess/fistula, or (7) a family history of inflammatory bowel disease.

        Exclusion Criteria:

          -  Acute bowel obstruction

          -  Intake of NSAIDs or acetylsalicylic acid ≤ 4 weeks before inclusion except
             prophylactic treatment with low dose Aspirin (≤ 150 mg per day)

          -  Pregnancy or lactation

          -  Alcohol or drug abuse

          -  Known gastrointestinal disorder other than inflammatory bowel disease

          -  Renal failure defined by a plasma-creatinine above the normal reference range

          -  Claustrophobia, cardiac pacemaker or implanted magnetic foreign bodies that precludes
             MREC

          -  Interpreter required or inability to understand the oral and written information

          -  Colonoscopy contraindicated, performed within 3 months or unwillingness to go through
             colonoscopy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacob B Brodersen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sydvestjysk Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacob B Brodersen, MD</last_name>
    <phone>+45 21298001</phone>
    <email>jacob.broder.brodersen@rsyd.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael D Jensen, MD PhD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sydvestjysk sygehus</name>
      <address>
        <city>Esbjerg</city>
        <zip>DK-6700</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacob B Brodersen, MD</last_name>
      <email>jacob.broder.brodersen@rsyd.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense university Hospital</name>
      <address>
        <city>Odense</city>
        <zip>DK-5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Kjeldsen, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sygehus Lillebaelt</name>
      <address>
        <city>Vejle</city>
        <zip>DK-7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael D Jensen, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2017</study_first_submitted>
  <study_first_submitted_qc>April 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2017</study_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sydvestjysk Hospital</investigator_affiliation>
    <investigator_full_name>Jacob Brodersen</investigator_full_name>
    <investigator_title>Specialist Registrat</investigator_title>
  </responsible_party>
  <keyword>Capsule endoscopy</keyword>
  <keyword>Crohn's disease</keyword>
  <keyword>Magnetic resonance enterography</keyword>
  <keyword>Ileocolonoscopy</keyword>
  <keyword>Bowel Ultrasound</keyword>
  <keyword>diagnostic imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

